CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from the Company’s oral, small molecule, complement C5 inhibitor program and data from the Company’s global, Phase 2 clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) will be presented at the 23rd Congress of the European Hematology Association (EHA) from June 14-17, 2018 in Stockholm, Sweden.
Details of the oral presentation are as follows:
Title: Characterization of Orally Bioavailable Small Molecule
Inhibitors of Complement C5
Session Title: Bone marrow failure syndromes incl. PNH – Biology & Translational Research
Presenter: Alonso Ricardo, Ph.D., Senior Vice President and Head of Research, Ra Pharma
Date/Time: Sunday, June 17, 8:15-8:30 CEST
Location: Room A8
Abstract Code: 3854
Details of the poster presentation are as follows:
Title: RA101495, A Subcutaneously-administered Peptide Inhibitor
of Complement Component C5, For the Treatment of Paroxysmal Nocturnal
Hemoglobinuria: Phase 2 Results
Session Title: Bone marrow failure syndromes incl. PNH – Clinical
Date/Time: Friday, June 15, 17:30-19:00 CEST
Location: Poster area
Abstract Code: 1430
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy and regulatory and clinical progress of our product candidates, including RA101495 SC, and statements regarding trial design, timeline and enrollment of our ongoing and planned clinical programs. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Ra Pharma's product candidates, including RA101495 SC, will not successfully be developed or commercialized; the risk that topline results as of February 7, 2017 from the Company's global Phase 2 clinical program evaluating RA101495 SC for the treatment of PNH may not be indicative of final study results; as well as the other factors discussed in the "Risk Factors" section in Ra Pharma's most recently filed Annual Report on Form 10-K, as well as other risks detailed in Ra Pharma's subsequent filings with the Securities and Exchange Commission . There can be no assurance that the actual results or developments anticipated by Ra Pharma will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Ra Pharma. All information in this press release is as of the date of the release, and Ra Pharma undertakes no duty to update this information unless required by law.